Drug intelligence / Profile preview

WIE-2301

Development stage: Preclinical
Lead developer: WhanIn Pharm
Modality: Small Molecules

Overview

**WIE-2301** is a Whanin Pharmaceutical development candidate for **essential hypertension**. Publicly available pipeline information identifies the program and its indication, while third-party pipeline indexing describes it as a preclinical chemical-drug candidate. Whanin has not publicly disclosed its molecular structure, pharmacologic target, mechanism of action, route of administration, dosage form, or formulation.

Beyond the preview

Go deeper on WIE-2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WIE-2301.

Explore the full profile